Loading...
HSChapter 30
U.S. imports of antisera and other blood fractions (HS 300212) totaled $298.2M in April 2026, traded with 49 countries.
Last updated: April 2026 dataAntisera, human blood plasma, immune sera, and fetal bovine serum (FBS) are high-value biological materials used in vaccine manufacturing, cell culture, diagnostics, and therapeutic applications, and all imports are subject to FDA Center for Biologics Evaluation and Research (CBER) oversight. The US schedule distinguishes human blood plasma (3002120010), normal human blood sera (3002120020), human immune blood sera (3002120030), fetal bovine serum (3002120040), and a residual blood fractions line (3002120090). Austria and Germany lead US supply under this heading, with Sweden and Spain also significant — a pattern consistent with Europe's established plasma fractionation and serum processing industries. Admissibility is complex; importers should consult a licensed customs broker and verify FDA CBER licensing or authorization requirements before shipment.
AI-written summary of the official U.S. Census Bureau trade figures on this page — verify before relying on it.
Yes. FBS derived from cattle may be subject to USDA APHIS import restrictions depending on the country of origin's bovine disease status, particularly regarding foot-and-mouth disease and bovine spongiform encephalopathy (BSE). Importers must verify both FDA CBER requirements and any applicable APHIS permits or country-of-origin restrictions before arranging shipment.
Normal human blood sera (3002120020) are derived from donors without specific immunization or disease exposure and are used primarily as reference standards or culture supplements, while human immune blood sera (3002120030) are collected from donors with elevated antibody titers against a specific pathogen or antigen. The intended use and donor selection criteria documented in the product specification are the primary basis for distinguishing between these two lines.
| Country | Imports | Exports | Balance |
|---|---|---|---|
| GERMANY | $28.9M | $306.9M | +$277.9M |
| AUSTRIA | $91.0M | $147.4M | +$56.5M |
| SWEDEN | $84.7M | $71.0M | -$13.7M |
| SPAIN | $6.4M | $73.9M | +$67.5M |
| SWITZERLAND | $15.2M | $63.0M | +$47.8M |
Supplier Network
Get discovered by U.S. importers searching for HS 300212 — Antisera and Other Blood Fractions. Be the first supplier listed.
Monthly import values over time